Spectral Medical Inc.

Spectral’s vision is to provide a personalized approach that will enable vastly improve outcomes for patients with septic shock. TSX: $EDT.TO

[Spectral Medical Inc. @SpectralMedical]

New topline data from the Phase 3 TIGRIS trial show that the mortality benefit observed with PMX at 28 and 90 days persisted through 12 months.
Read the full announcement and topline results: https://t.co/urIE1kSVUP

$EDT.TO

[Spectral Medical Inc. @SpectralMedical]

We’re excited to announce that our clinical consultant, Debra Foster, will be speaking at the 2026 Unite for Sepsis Symposium:
June 12-11:10 AM – 11:55 AM
Immune Failure and Endotoxin Signaling in Sepsis: Rethinking the Host Response

Learn more: https://t.co/s6PmloQecz

[Sepsis Alliance @SepsisAlliance]

The Unite for Sepsis Symposium is just over a week away - have you made plans to join us for this collaborative, in-person event? There are still tickets available! Visit https://t.co/38UicZjoTD to learn more.

Thank you to the incredible sponsors who are supporting this inspiring event:

Prenosis
@biomerieux
@Vivacelle
Efferon
@BeckmanDx
@VantiveHealth
@SpectralMedical
@hikmapharma
@AdvaMedDx
Clairyon
@Inflammatix_Inc
Gener8
@Flosonics
@thermofisher
@Opticyte_Inc
@PhRMA
@Cytovale
@RainsureS

[Spectral Medical Inc. @SpectralMedical]

Understanding measurable biology may help refine how future therapies and studies are designed in critically ill populations.

Precision medicine in sepsis: lessons from the TIGRIS trial and the reawakening of targeted therapy. 2026 https://t.co/nBRinQOcuF

#FOAMed #CriticalCare

[Spectral Medical Inc. @SpectralMedical]

The submission is supported by data from the Phase 3 TIGRIS trial, with full 90-day results published earlier this year in The Lancet Respiratory Medicine.

Read the full press release: https://t.co/aR1mvEuVMP

#Sepsis #SepticShock #CriticalCare $EDT.TO

[Spectral Medical Inc. @SpectralMedical]

Join us at the 44th Vicenza Course in Vicenza, Italy, for “Meet the Professor” with Dr. Paul Walker, discussing the origins and clinical rationale behind the Endotoxin Activity Assay (EAA™) and its role in precision approaches to septic shock.

June 16 | 13:45 | Room Tiziano A

[Spectral Medical Inc. @SpectralMedical]

Biological heterogeneity in septic shock may have influenced outcomes in prior sepsis trials, raising important questions about whether broad syndrome-based enrollment can dilute therapeutic effect.

Read the full publication: https://t.co/6Q10tfgWql

#FOAMed #Sepsis

[Spectral Medical Inc. @SpectralMedical]

Endotoxin biology and biomarker-guided approaches in critical illness will be featured at the 44th Vicenza Course, including sessions from Dr. Javier Neyra on the TIGRIS trial and Dr. John Kellum on endotoxin in HRS-AKI.
Learn more: https://t.co/l9aWb6VgvW
#AKI #Nephrology

[Spectral Medical Inc. @SpectralMedical]

At the 63rd ERA Congress, TIgris investigator Prof. Dr. Blaithin McMahon will present: Polymyxin B haemoadsorption in endotoxic septic shock (TIGRIS), a Phase 3 Bayesian RCT.

🗓 June 4 | 17:15 BST
📍 Glasgow + Virtual

Join the conversation: https://t.co/0TnUloLLQm

#MedEd

[Spectral Medical Inc. @SpectralMedical]

A new publication in the Journal of Anesthesia, Analgesia and Critical Care explores how the TIGRIS trial applied a biology-informed approach in septic shock using endotoxin activity and organ dysfunction severity for patient selection.

👉 https://t.co/6Q10tfgWql

#FOAMed

[Spectral Medical Inc. @SpectralMedical]

Spectral's Chief Medical Officer, Dr. John Kellum was pleased to join Professor Rob Mac Sweeney and @CritCareReviews to discuss the TIGRIS Trial.

Listen here: https://t.co/WmlrmR0wCP

#MedEd

[Critical Care Reviews @CritCareReviews]

TIGRIS Trial

➡️ Polymyxin B haemoadsorption in endotoxic septic shock

➡️ Strong physiological rationale
➡️ Long-standing concept
➡️ But does it actually improve outcomes?

➡️ We spoke to Chief Investigator John Kellum

CCR Podcast
https://t.co/7C0R4QDOi2

[Spectral Medical Inc. @SpectralMedical]

Spectral has announced continued progress toward its planned U.S. FDA PMA submission for Toraymyxin™ (PMX), targeted for May 29, 2026.

Read the press release for additional details on the PMA timeline, TIGRIS findings, and corporate updates. 👉 https://t.co/M9rAhecvdx
$EDT.TO

[Spectral Medical Inc. @SpectralMedical]

Earlier initiation of Polymyxin B hemoperfusion was associated with improved outcomes in septic shock.

Meta-analysis signals:
• Lower mortality
• Improved oxygenation
• Faster organ recovery

Timing and patient selection remain key.👉 SCCM Abstract: https://t.co/Tlrn7J3p15

[Spectral Medical Inc. @SpectralMedical]

Reminder: Endotoxemia & Sepsis in Zagreb

Join these world-renowned experts for a deep dive into patient selection, trial implications, and the clinical reality of targeted endotoxin removal.

May 8 | 14:40–15:40
https://t.co/Ils9AdGONL

[Spectral Medical Inc. @SpectralMedical]

A review in Critical Care evaluates over two decades of published evidence on the use of the Endotoxin Activity Assay in sepsis. Across 50+ studies and 6,200+ patients, endotoxin activity is consistently associated with disease severity.
👉 https://t.co/2bXxq8TFGT

#CriticalCare

[Spectral Medical Inc. @SpectralMedical]

Pathogen characteristics shape sepsis phenotypes.

Gram-negative infections are linked to hyperinflammatory responses and higher 90-day mortality.

Supporting more precise approaches in a significant global health issue.
👉 https://t.co/5k5VjGMqB8

#SepticShock #ICU $EDT.TO

[Spectral Medical Inc. @SpectralMedical]

Spectral is proud to once again support the Unite for Sepsis Symposium hosted by Sepsis Alliance.

🗓 June 11–12, 2026
📍 Washington, D.C.

More than a symposium—it’s a collaborative movement to advance sepsis care.
Registration now open: https://t.co/xaZrI5BNlh

#UniteForSepsis

[Spectral Medical Inc. @SpectralMedical]

Join us at the Bloom Burton & Co. Healthcare Investor Conference!

Spectral CEO Chris Seto presents on Wednesday, April 22, at 10:30 AM ET. Our team is also available for 1-on-1 meetings throughout the day.

Register: https://t.co/x5CN4Tb6KQ

#MedTech #Sepsis #Investing $EDT.TO

[Spectral Medical Inc. @SpectralMedical]

Save the Date: Endotoxemia & Sepsis in Zagreb
Join these world-renowned experts for a deep dive into patient selection, trial implications, and the clinical reality of targeted endotoxin removal.
May 8 | 14:40–15:40
👉 https://t.co/Ils9AdGONL

[Spectral Medical Inc. @SpectralMedical]

TIGRIS Phase 3 results:
“Publication in The Lancet Respiratory Medicine reflects the scientific rigor of the Tigris trial and the strength of the data supporting these findings,” said Dr. Matthieu Legrand, corresponding author of the Tigris manuscript..."
https://t.co/1itr3KnhaP